Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
20 hedge funds and large institutions have $5.91M invested in Aptose Biosciences, Inc. in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
83% more capital invested
Capital invested by funds: $3.23M → $5.91M (+$2.68M)
18% more funds holding
Funds holding: 17 → 20 (+3)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$4.93M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.4K |
| 3 |
NFG
Noven Financial Group
Denver,
Colorado
|
+$30.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$24.6K |
| 5 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$477K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$365K |
| 3 |
Morgan Stanley
New York
|
-$111K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$64.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30.5K |
APTO Hedge Fund Activity: Q4 2018 in Review
20 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2018, worth a combined $5.91M — up 83% from $3.23M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new APTO positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was DRW Securities, adding an estimated $4.93M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $477K sold.
- 20 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2018, up from 17 in Q3 2018.
- Funds reported $5.91M of Aptose Biosciences, Inc. stock for Q4 2018, up 83% quarter-over-quarter.
- 5 funds opened new Aptose Biosciences, Inc. positions in Q4 2018 and 2 closed out, a net change of +3 holders.
- The largest Aptose Biosciences, Inc. buyer in Q4 2018 was DRW Securities, an estimated $4.93M added.
- The largest Aptose Biosciences, Inc. seller in Q4 2018 was Renaissance Technologies, an estimated $477K sold.
Based on aggregated 13F filings for Q4 2018.